The Board of GeNeuro


Jesús Martin-Garcia
Jesús began his career in 1983 at the World Economic Foundation, and in 1989 at McKinsey & Co where he led studies in the pharmaceutical and food industries. By 1993, he chose the entrepreneurial path by creating, investing and leading start-ups in Switzerland and the United States. He was for example a co-founder of LeShop in 1996, which became the Swiss leader in e-commerce and was sold to Migros. In 2003, he created Eclosion, a public-private partnership for translating scientific discoveries in the field of life sciences into innovative drugs with disruptive potential. This unique structure was instrumental in the creation of GeNeuro, which was led by Jesús since its creation in 2006. Jesús holds a bachelor's degree in industrial sciences, a master in law from Geneva University and an MBA from Harvard Business School. He serves on the board of several biotech companies and industrial and business associations.


Marc Bonneville
Marc has served on the Board of the Company since November 2015. He is a veterinary doctor and was a research director of the National Centre for Scientific Research (CNRS), before joining the Institut Mérieux in 2013 as Vice President in charge scientific and medical affairs. He began his career in 1983 in the field of transplantation immunology in Nantes, then at the Massachusetts Institute of Technology (Cambridge, MA) in Prof. Susumu Tonegawa’s team (1987 Nobel Prize for Physiology and Medicine). From 1990 to 2013, Marc Bonneville led a research group working on human cellular immune responses within UMR892 INSERM (Nantes), that he directed for 17 years. He co-founded the biotech company Innate Pharma SA in 1999, which develops immunotherapeutic approaches in oncology and infectious diseases that target innate lymphocytes and their receptors. Marc is the author of over 200 publications and eight patents and has won several awards and recognitions (bronze and silver medal of CNRS, Halpern’s prize, Foundation for Medical Research and League against Cancer, etc.). He has been involved in about thirty committees and scientific boards, and was an advisor to the Director General of INSERM from 2000 to 2007 in the areas of immunology, infectious diseases and biotherapies.


Michel Dubois
Michel is a Director at GeNeuro SA and President of GeNeuro Innovation SAS. He is also a Director at Stallergénes and at the Hospital St Luc St Joseph in Lyon. Michel is Honorary Consul of Canada in Lyon. He was the Director General of Institut Mérieux and a consultant at McKinsey and Arthur Andersen.


Eric Falcand
Eric has served on the Board of the Company since November 2015. He holds a Doctorate in Veterinary Medicine from the Veterinary School of Lyon. He also holds a Masters in Pharmaceutical Management from the Institute of Industrial Pharmacy of Lyon, and an MBA from the Management School of Lyon. Eric began his career within Virbac Laboratories from 1988 to 1991 in marketing and sales management positions, before managing promotional and commercial organizations in geographic areas within Synthelabo Laboratories (Sanofi) between 1991 and 1997. He then joined Servier and became General Manager of the subsidiary in Russia, before becoming CEO of Servier in the UK in 2002. He joined the Business Development & Licensing team in 2008 and has led it as Vice-President in 2015.


Dr. Gordon Francis 
Gordon is a neurologist with outstanding expertise in the treatment of multiple sclerosis. He has played a key role in the approval of several leading MS drugs. As Vice President, Therapeutic Area Head, Neurology with Novartis, Gordon was responsible for the development and registration of Gilenya®, the world’s first oral MS treatment. Prior to Novartis, he led the team responsible for the approval and launch of Tysabri® at Elan; and earlier, he spearheaded the approval of Rebif® with Serono. Gordon previously headed the MS Clinical Research Clinic at McGill and the Clinical Research Center at the Montreal Neurological Institute. He graduated from Queen’s University medical school in Kingston, completed Internal Medicine and Neurology training at McGill University and post-doctoral Neuroimmunology training at UCSF. Gordon has published over 100 peer reviewed articles in the field of neurology.


Christophe Guichard
Christophe has been managing corporate finance activities in strong growth environments since 1994, first within KPMG/Salustro and then as the CFO of Trader Classified Media, performing major M&A transactions including two IPOs (Nasdaq / Euronext and LSE), senior debt financings, acquisitions and divestitures. Since 2008, Christophe has been a Partner and Chief Financial Officer of Eclosion2 & Cie SCPC, and acted as the CFO of GeNeuro from 2008, in charge of Finance, HR and legal, until his nomination as a member of the Board of Directors of the Company in November 2015. Christophe graduated from EDHEC Business School, holds the DESCF (Expertise in Finance and Accounting) and graduated from Harvard Business School.


Hedi Ben Ibrahim
Hedi is a graduate of the Ecole Polytechnique and the Ecole Nationale Supérieure des Mines in Paris. He previously occupied varied positions within Vallourec Group and in the public sector. He has been the vice-president for Immunotherapy at Institut Mérieux since September 2018. Hedi is also a director of Transgene and the chairman of the board of ABL Inc (both companies being part of the Mérieux group), and is the chairman of the supervisory board of Fab’Entech.


Giacomo di Nepi
Giacomo was Executive Vice President and Managing Director for InterMune in Europe, where he built the European organization and led the launch of Esbriet®, one of the most successful orphan drug launches in Europe. From 2006 to 2008, Giacomo was CEO of Takeda Pharmaceuticals, Europe. Between 1996 and 2006, he held various roles with Novartis, most recently as a member of the Pharma Executive Committee and Global Head of the Transplantation, Immunology and Infectious Diseases Business Unit after being CEO of Novartis Italy. Giacomo had been a Partner with McKinsey & Co. and he served as Vice President of Farmindustria, the Italian Industry Association, and as a member of the EFPIA Heads of Europe Committee. Giacomo holds a degree in Economics from Bocconi University, Milan, and an MBA from INSEAD, Fontainebleau.